Avident Health and Unite for HER Secure Grant to Advance Metastatic Breast Care

GTTP

Pfizer and NCCN grant funds new digital oncology navigation initiative.
MyNavigator platform delivers personalized NCCN education to patients.
Unite for HER provides seamless access to integrative supportive therapies.
Program actively engages family caregivers to improve treatment adherence.

Impact - Why it Matters

This initiative represents a vital shift toward continuous, home-based oncology navigation. By integrating NCCN clinical standards with essential supportive care, the partnership addresses the critical gap between hospital visits, ultimately improving long-term adherence and quality of life for patients and caregivers navigating complex metastatic treatment pathways.

Summary

Avident Health LLC and Unite for HER have been awarded a prestigious quality improvement grant from Pfizer and the National Comprehensive Cancer Network (NCCN). This strategic partnership aims to enhance care for patients with metastatic breast cancer by deploying the MyNavigator digital platform. The initiative bridges the gap between clinical visits, ensuring patients receive consistent, evidence-based education and vital supportive services throughout their treatment journey.

The project leverages MyNavigator™ to translate complex NCCN Guidelines into accessible, personalized modules while streamlining access to Unite for HER’s integrative therapies, such as nutritional counseling and mental health support. By including informal family caregivers in the digital communication loop, the platform fosters improved treatment adherence, proactive symptom monitoring, and better overall quality of life for patients managing the complexities of metastatic cancer.

This collaboration represents a significant step toward patient-centered oncology navigation, effectively reducing the burden on clinical teams while empowering families. By capturing real-time symptom trends and streamlining support, the initiative seeks to prevent avoidable complications and improve patient outcomes. The project will rigorously evaluate key metrics, including patient knowledge, decisional conflict, and therapy adherence, to establish a scalable model for future cancer care innovation.